Confident Investing Starts With TipRanks Premium

Get 55% Off
TipRanks
Go Ultimate55% OFF

AbbVie (ABBV) Drug Pipeline

Drug pipeline
Drug NameConditionStageStatusStudy NameTrial Start DateArticle
Abbv-7828Healthy SubjectsPhase IRecruitingA Single Ascending Dose, and Food Effect Study of ABBV-7828 in Healthy AdultsSep 28, 2026―
Onabotulinumtoxina, Skinvive, Volux, VolumaJawline And Neck AppearancePhase IVRecruitingStudy to Assess Participant Satisfaction After Jawline and Neck TreatmentAug 27, 2026
Etentamig, Dexamethasone, Daratumumab, Cyclophosphamide, BortezomibAmyloid Light Chain (Al) AmyloidosisPhase IIINot Yet RecruitingStudy to Evaluate Change in Disease Activity and Adverse Events of Subcutaneous Etentamig Compared With Daratumumab Plus Cyclophosphamide Plus Bortezomib Plus Dexamethasone (Dara-CyBorD) in Adults With Amyloid Light Chain (AL) AmyloidosisAug 26, 2026
UpadacitinibSevere Alopecia AreataPhase IIIRecruitingA Study to Evaluate the Safety and Effectiveness of Upadacitinib in Pediatric Participants With Alopecia AreataAug 11, 2026
Carboplatin, Pembrolizumab, Paclitaxel, Abbv-1480, Nab- PaclitaxelNon-small Cell Lung CancerPhase IIINot Yet RecruitingA Study to Assess Intravenous ABBV-1480 Combined With Chemotherapy Versus Pembrolizumab Combined With Chemotherapy for the First Line Treatment of Locally Advanced/Metastatic Non-Small Cell Lung Cancer in Adult ParticipantsAug 07, 2026
Botox, Agn-151586Glabellar LinesPhase IRecruitingA Study to Evaluate Sequential Administration of Injections of AGN-151586 Followed by BOTOX in Adult Participants for Treatment of Glabellar LinesAug 07, 2026
Abbv-295Obesity, OverweightPhase IIRecruitingSafety and Efficacy of ABBV-295 in Adults With Obesity or Overweight With Weight-Related ComorbiditiesAug 04, 2026
Telisotuzumab Adizutecan, Carboplatin, Fluorouracil, Cisplatin, PembrolizumabHead And Neck Squamous Cell CarcinomaPhase IIRecruitingA Study to Assess Adverse Events, Change in Disease Activity and Optimal Dose of Intravenous (IV) Telisotuzumab Adizutecan With IV Pembrolizumab for First-Line Treatment of Adult Participants With Recurrent or Metastatic Head and Neck Squamous Cell CarcinomaJul 30, 2026
Abbv-859Healthy VolunteerPhase IRecruitingA Study to Assess the Safety, Tolerability and How Single Ascending Doses of ABBV-859 Moves Through the Body of Healthy Adult ParticipantsJul 27, 2026
Agn-151586Forehead LinesPhase IIActive Not RecruitingA Study to Assess the Safety and Efficacy of AGN-151586 Injections for the Treatment of Moderate to Severe Forehead Lines (FHL) in Adult ParticipantsJul 23, 2026

FAQ

What are the FDA phases for drug approval?
The FDA approval process for new drugs is divided into several phases: a. Preclinical testing b. Phase 1 – Safety and dosage c. Phase 2 – Effectiveness and side effects d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
What is a clinical trial?
A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.
What drugs does Abbvie (MX:ABBV) have in its pipeline
AbbVie MX:ABBV is currently developing the following drugs: Abbv-7828, Onabotulinumtoxina, Skinvive, Volux, Voluma, Etentamig, Dexamethasone, Daratumumab, Cyclophosphamide, Bortezomib, Upadacitinib, Carboplatin, Pembrolizumab, Paclitaxel, Abbv-1480, Nab- Paclitaxel, Botox, Agn-151586, Abbv-295, Telisotuzumab Adizutecan, Carboplatin, Fluorouracil, Cisplatin, Pembrolizumab, Abbv-859, Agn-151586, Risankizumab, Abbv-701, Trosunilimab, Abbv-382, Abbv-066, Abbv-313, Agn-151607-Dp, Itraconazole, Nacresertib, Abbv-519, Bretisilocin, Abbv-1758, Emraclidine, Itraconazole, Abbv-722, Venetoclax, Azacitidine, Pivekimab Sunirine, Abbv-1451, Nacresertib, Midazolam, Metformin, Digoxin, Sitagliptin, Pitavastatin, Abbv-722, Sham, Artificial Tears, Surabgene Lomparvovec, Topical Steroid, Bevacizumab, Telisotuzumab Adizutecan, Trifluridine/Tipiracil, Abbv-722, Ethinyl Estradiol + Levonorgestrel, Oxaliplatin, Irinotecan, Telisotuzumab Adizutecan, Fluorouracil, Folinic Acid/ Leucovorina, Risankizumab, Upadacitinib, Abbv-722, Abbv-295, Levonorgestrel/Ethinyl Estradiol, Abbv-8736, Abbv-438, Venetoclax, Topotecan, Amrubicin, Lurbinectedin, Abbv-706, Abbv-722, Abbv-243, Pivekimab Sunirine, Abbv-444, Refresh Optive Ud. These drug candidates are in various stages of clinical development as the company works toward FDA approval.